Fluid metabolic pathways after subarachnoid hemorrhage.
Jiru ZhouPeiwen GuoZongduo GuoXiaochuan SunYu-Jie ChenHua FengPublished in: Journal of neurochemistry (2021)
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular disease with high mortality and morbidity. In recent years, a large number of studies have focused on the mechanism of early brain injury (EBI) and delayed cerebral ischemia (DCI), including vasospasm, neurotoxicity of hematoma and neuroinflammatory storm, after aSAH. Despite considerable efforts, no novel drugs have significantly improved the prognosis of patients in phase III clinical trials, indicating the need to further re-examine the multifactorial pathophysiological process that occurs after aSAH. The complex pathogenesis is reflected by the destruction of the dynamic balance of the energy metabolism in the nervous system after aSAH, which prevents the maintenance of normal neural function. This review focuses on the fluid metabolic pathways of the central nervous system (CNS), starting with ruptured aneurysms, and discusses the dysfunction of blood circulation, cerebrospinal fluid (CSF) circulation and the glymphatic system during disease progression. It also proposes a hypothesis on the metabolic disorder mechanism and potential therapeutic targets for aSAH patients.
Keyphrases
- subarachnoid hemorrhage
- brain injury
- cerebral ischemia
- end stage renal disease
- clinical trial
- cerebrospinal fluid
- chronic kidney disease
- phase iii
- newly diagnosed
- ejection fraction
- blood brain barrier
- peritoneal dialysis
- prognostic factors
- open label
- randomized controlled trial
- mouse model
- study protocol
- quality improvement